4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lungs ventilation analysis software; Permetium, a preclinical imaging system which quantify regional changes in pulmonary function; and AccuVent 200, a small animal ventilator. The company was incorporated in 2012 and is based in Carlton, Australia.
| Market Capitalization | $210.5309 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | |
| Book Value | 0.199 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.1 |
| EBITDA | -42,004.56 |
| Profit Margin | 0 |
| Operating Margin TTM | -62.0249 |
| Return on Assets TTM | -0.3331 |
| Return on Equity TTM | -0.4804 |
| Revenue TTM | 718.581 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2016-12-31 | 681.86 | 0.68 | 681.18 | |
| 2017-12-31 | 789.26 | 1,030.92 | -241.66 | |
| 2018-12-31 | 695 | 631.39 | 63.61 | |
| 2019-12-31 | 1,232.5 | 1,121.11 | 111.39 | |
| 2020-12-31 | 216.978 | 91.853 | 125.125 | 24,555.733 |
| 2021-12-31 | 1,054.3 | 773.683 | 280.617 | 37,804.874 |
| 2022-12-31 | 718.58 | 34.15 | 684.43 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2016-12-31 | 1,153.62 | 4,945.95 | 1,696.43 | 0 | 7,679.688 | |
| 2017-12-31 | 1,662.7 | 5,452.49 | 1,674.26 | 1,000 | 11,473.199 | |
| 2018-12-31 | 3,085.22 | 9,024.2 | 4,468.51 | 0 | 1,500 | 17,705.138 |
| 2019-12-31 | 8,429.19 | 15,824.6 | 27,634.45 | 17,054.77 | 621.15 | 18,927.393 |
| 2020-12-31 | 80,880.062 | 92,636.603 | 9,280.013 | 723.452 | 141,587.808 | |
| 2021-12-31 | 51,114.537 | 74,313.191 | 14,802.199 | 1,100.445 | 141,718.799 | |
| 2022-12-31 | 69,576.37 | 92,923.52 | 21,463.14 | 0 | 184,359.11 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2016-12-31 | -3,973.937 | -2,158.364 | 934.661 | |||
| 2017-12-31 | -3,936.98 | -3,378.717 | 509.081 | |||
| 2018-12-31 | -6,491.005 | -5,778.913 | 1,422.528 | |||
| 2019-12-31 | -21,975.379 | -7,650.348 | 5,343.968 | 8,429.192 | ||
| 2020-12-31 | -21,420.531 | -14,520.004 | 72,450.87 | 8,429.192 | 80,880.062 | |
| 2021-12-31 | -24,592.876 | -25,269.278 | -29,765.525 | 80,880.062 | 51,114.537 | |
| 2022-12-31 | -31,459.798 | 18,461.836 | 51,114.537 | 69,576.373 |